Last week, the US Food and Drug Administration announced that tirzepatide is no longer in shortage. It has been a long time coming: The active ingredient in the weight-loss drug Zepbound and diabetes medication Mounjaro has experienced runaway popularity, along with other GLP-1 meds like Ozempic. This unprecedented demand sent it into shortage in December 2022. The end of drug shortages are usually a good thing—but for many people currently taking tirzepatide, this is a moment of fear and uncertainty rather than celebration. For them, this means the meds they are accustomed to taking may be harder to get.
“Absolutely devastating,” says Tennessee-based Gianna Green, who has taken the drug